MCID: MLG079
MIFTS: 46

Malignant Pleural Mesothelioma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Malignant Pleural Mesothelioma

MalaCards integrated aliases for Malignant Pleural Mesothelioma:

Name: Malignant Pleural Mesothelioma 12 37 15 73
Malignant Mesothelioma of Pleura 12
Pleural Malignant Mesothelioma 55

Classifications:



External Ids:

Disease Ontology 12 DOID:7474
ICD10 33 C45.0
NCIt 50 C7376
KEGG 37 H00015
UMLS 73 C0812413

Summaries for Malignant Pleural Mesothelioma

Disease Ontology : 12 A pleural cancer that has material basis in mesothelium cells.

MalaCards based summary : Malignant Pleural Mesothelioma, also known as malignant mesothelioma of pleura, is related to mesothelioma, malignant and sarcomatoid mesothelioma, and has symptoms including chest pain, dyspnea and fatigue. An important gene associated with Malignant Pleural Mesothelioma is PVT1 (Pvt1 Oncogene
Our results suggest that C-MYC and PVT1 CNG promotes a malignant phenotype of MPM,with C-MYC CNG stimulating cell proliferation and PVT1 both stimulating proliferation and inhibiting apoptosis.
Dysfunction Pattern: Regulation [up-regulated]), and among its related pathways/superpathways is FGF signaling pathway. The drugs Alimta and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and endothelial, and related phenotype is normal.

Related Diseases for Malignant Pleural Mesothelioma

Diseases in the Benign Pleural Mesothelioma family:

Malignant Pleural Mesothelioma

Diseases related to Malignant Pleural Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Related Disease Score Top Affiliating Genes
1 mesothelioma, malignant 30.8 BAP1 CALB2 CDH2 MSLN NKX2-1 SPP1
2 sarcomatoid mesothelioma 30.4 NKX2-1 THBD WT1
3 lung cancer susceptibility 3 29.7 CALB2 GAS5 MET MSLN NKX2-1
4 renal cell carcinoma, nonpapillary 29.4 GAS5 MET NKX2-1 PVT1 WT1
5 pancreatic cancer 28.4 BIRC5 ENSG00000261211 GAS5 MET MSLN PVT1
6 lung cancer 27.5 BIRC5 GAS5 MET NKX2-1 PVT1 SNHG7
7 fallopian tube carcinosarcoma 10.8 CALB2 WT1
8 mucinous bronchioloalveolar adenocarcinoma 10.7 CALB2 NKX2-1
9 venous hemangioma 10.7 CALB2 WT1
10 lymphohistiocytoid mesothelioma 10.6 CALB2 THBD
11 malignant epithelial mesothelioma 10.6 THBD WT1
12 peritoneum cancer 10.6 BAP1 WT1
13 pericardium cancer 10.5 CALB2 MSLN THBD
14 rete testis adenocarcinoma 10.5 CALB2 NKX2-1 THBD
15 pericardial mesothelioma 10.5 CALB2 MSLN THBD
16 adenomatoid tumor 10.5 CALB2 THBD WT1
17 rete testis neoplasm 10.5 CALB2 NKX2-1 THBD
18 peritoneal mesothelioma 10.4 BAP1 THBD WT1
19 spindle cell liposarcoma 10.4 CALB2 WT1
20 ovarian brenner tumor 10.4 CALB2 THBD WT1
21 sertoli-leydig cell tumor 10.3 CALB2 WT1
22 malignant biphasic mesothelioma 10.3 CALB2 MSLN THBD WT1
23 kidney cancer 10.2 GAS5 MET PVT1
24 adenocarcinoma 10.2
25 endotheliitis 10.2
26 thyroid cancer, nonmedullary, 1 10.1 GAS5 NKX2-1 PVT1
27 adamantinoma of long bones 10.1 BIRC5 GAS5 PVT1 SPP1
28 clear cell renal cell carcinoma 10.1 BIRC5 MET PVT1
29 sertoli cell tumor 10.1 CALB2 WT1
30 pneumothorax, primary spontaneous 10.1
31 small cell cancer of the lung 10.1
32 pneumothorax 10.1
33 mediastinitis 10.1
34 pleural cancer 10.0 BAP1 CALB2 MSLN SPP1 TYMS WT1
35 benign mesothelioma 10.0 CALB2 NKX2-1 THBD TYMS WT1
36 esophageal cancer 10.0
37 wilms tumor 5 10.0
38 wilms tumor 6 10.0
39 asbestosis 10.0
40 sarcoma 10.0
41 esophagitis 10.0
42 squamous cell carcinoma 10.0
43 cervicitis 10.0
44 breast cancer 9.8
45 intussusception 9.8
46 scleroderma, familial progressive 9.8
47 wilms tumor 1 9.8
48 ataxia-telangiectasia 9.8
49 lymphoma, hodgkin, classic 9.8
50 cervical cancer 9.8

Graphical network of the top 20 diseases related to Malignant Pleural Mesothelioma:



Diseases related to Malignant Pleural Mesothelioma

Symptoms & Phenotypes for Malignant Pleural Mesothelioma

UMLS symptoms related to Malignant Pleural Mesothelioma:


chest pain, dyspnea, fatigue, chills, malaise

MGI Mouse Phenotypes related to Malignant Pleural Mesothelioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 9.23 BIRC5 CALB2 MET MSLN NKX2-1 THBD

Drugs & Therapeutics for Malignant Pleural Mesothelioma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Alimta 18 49 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004

Drugs for Malignant Pleural Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 181)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
4
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
5
Hydroxocobalamin Approved Phase 2, Phase 3,Phase 3 13422-51-0 11953898 44475014
6
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
7
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
8
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
9
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
10
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
11
Raltitrexed Approved, Investigational Phase 3,Phase 1,Phase 2 112887-68-0 104758
12
Vorinostat Approved, Investigational Phase 3,Phase 1,Phase 2 149647-78-9 5311
13
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
14
nivolumab Approved Phase 3,Phase 2 946414-94-4
15
Pembrolizumab Approved Phase 3,Phase 1,Phase 2 1374853-91-4
16
Nintedanib Approved Phase 3,Phase 2 656247-17-5 56843413
17
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
18
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 2, Phase 3,Phase 3 13422-55-4
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
20
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3,Phase 3 68-19-9 44176380
21
Doxil Approved June 1999 Phase 3,Phase 2 31703
22 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
23 Analgesics Phase 3,Phase 2,Phase 1
24 Micronutrients Phase 3,Phase 2
25 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
26 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
27 Trace Elements Phase 3,Phase 2
28 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
29 Vitamin B 12 Phase 2, Phase 3,Phase 3
30 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
31 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
32 Vitamin B Complex Phase 3,Phase 2,Phase 1
33 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
34 Vitamins Phase 2, Phase 3,Phase 3
35 Antibodies Phase 3,Phase 2,Phase 1
36 Immunoglobulins Phase 3,Phase 2,Phase 1
37 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
38 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
39 Anti-Infective Agents Phase 3,Phase 2,Phase 1
40 Antiemetics Phase 3,Phase 2,Phase 1
41 BB 1101 Phase 3,Phase 2,Phase 1
42 Antimetabolites Phase 3,Phase 2,Phase 1
43 Antiviral Agents Phase 3,Phase 2,Phase 1
44 Autonomic Agents Phase 3,Phase 2,Phase 1
45 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
46 Antimitotic Agents Phase 3,Phase 2,Phase 1
47 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
48 Alkylating Agents Phase 3,Phase 2,Phase 1
49 Mitomycins Phase 3
50 Histone Deacetylase Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 194)
# Name Status NCT ID Phase Drugs
1 NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed Completed NCT01098266 Phase 3 NGR-hTNF plus Best Investigator's Choice (BIC);Placebo plus Best Investigator's Choice (BIC)
2 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1) Completed NCT00128102 Phase 3 vorinostat;Placebo
3 Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3 cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
4 Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery Completed NCT00005636 Phase 3 cisplatin;pemetrexed disodium
5 Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura Completed NCT00004920 Phase 3 cisplatin;raltitrexed
6 A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma Completed NCT00190762 Phase 3 Pemetrexed
7 Mesothelioma Avastin Plus Pemetrexed-cisplatin Study Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
8 Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 Completed NCT01836575 Phase 3 Pemetrexed;Carboplatin
9 Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Recruiting NCT02709512 Phase 2, Phase 3 ADI-PEG 20 plus Pem Cis
10 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma Active, not recruiting NCT02991482 Phase 3 Pembrolizumab;Gemcitabine;Vinorelbine
11 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients Active, not recruiting NCT02899299 Phase 3 Pemetrexed;Cisplatin;Carboplatin
12 Nintedanib (BIBF 1120) in Mesothelioma Active, not recruiting NCT01907100 Phase 3 Nintedanib;Pemetrexed;Cisplatin;Cisplatin;Pemetrexed;Placebo
13 PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Terminated NCT01604005 Phase 3
14 A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma Unknown status NCT01279967 Phase 2 ADI-PEG 20
15 Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma Unknown status NCT01358084 Phase 2 NGR-hTNF;Placebo
16 Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma Unknown status NCT00886028 Phase 2 Liposomal doxorubicin;Cisplatin
17 Trimodal Lung-Sparing Treatment of Pleural Mesothelioma Unknown status NCT00859495 Phase 2 Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
18 Four Versus Six Cycles of Pemetrexed/Platinum for MPM Unknown status NCT02497053 Phase 2 pemetrexed/platinum chemotherapy;Pemetrexed/platinum chemotherapy
19 Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2 cisplatin;methotrexate;vinorelbine ditartrate
20 A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma Unknown status NCT01569919 Phase 2 Pemetrexed;Cisplatin;Dexamethasone
21 A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
22 A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma Unknown status NCT01649024 Phase 2 Tremelimumab
23 The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma Unknown status NCT01655888 Phase 2 Tremelimumab
24 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
25 Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma Unknown status NCT01281800 Phase 2
26 Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. Completed NCT01721018 Phase 1, Phase 2
27 Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00386815 Phase 2 pemetrexed;cisplatin
28 Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment Completed NCT01243632 Phase 2 Prolonged 6-hr infusion of gemcitabine
29 A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma Completed NCT01486368 Phase 2 PF-03446962
30 Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Completed NCT00484276 Phase 2 NGR-hTNF
31 Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity Completed NCT01024946 Phase 2 everolimus
32 Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma Completed NCT00272558 Phase 2 Carboplatin and Vinorelbine
33 Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma Completed NCT02662504 Phase 2 Adjuvant chemotherapy
34 Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy Completed NCT01265433 Phase 2
35 Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) Completed NCT00700336 Phase 1, Phase 2 pemetrexed, cisplatin and CBP501;pemetrexed and cisplatin
36 Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma Completed NCT01112293 Phase 2 GC1008
37 Pazopanib in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00459862 Phase 2 pazopanib hydrochloride
38 Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00251550 Phase 1, Phase 2 Pemetrexed;Cisplatin
39 Bortezomib in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00513877 Phase 2 bortezomib
40 S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery Completed NCT00243074 Phase 2 cediranib maleate
41 An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma Completed NCT00738582 Phase 2 MORAb-009 (Amatuximab);Pemetrexed;Cisplatin
42 Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00227630 Phase 2 cisplatin;pemetrexed disodium
43 Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma Completed NCT00392444 Phase 2 sunitinib malate
44 Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma Completed NCT00407459 Phase 2 Bevacizumab, Pemetrexed, Carboplatin
45 Nivolumab in Patients With Recurrent Malignant Mesothelioma Completed NCT02497508 Phase 2 nivolumab
46 S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery Completed NCT00770120 Phase 2 everolimus
47 A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma. Completed NCT00996567 Phase 2 Cetuximab (Erbitux)
48 Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00004033 Phase 2 liposomal NDDP
49 Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma Completed NCT00101283 Phase 2 pemetrexed disodium;gemcitabine hydrochloride;carboplatin
50 Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate Completed NCT00165516 Phase 2 Cisplatin;Sodium Thiosulfate

Search NIH Clinical Center for Malignant Pleural Mesothelioma

Genetic Tests for Malignant Pleural Mesothelioma

Anatomical Context for Malignant Pleural Mesothelioma

MalaCards organs/tissues related to Malignant Pleural Mesothelioma:

41
Lung, T Cells, Endothelial, Testes, Liver, Thymus, Lymph Node

Publications for Malignant Pleural Mesothelioma

Articles related to Malignant Pleural Mesothelioma:

(show top 50) (show all 869)
# Title Authors Year
1
Correction: Apoptosis by [Pt(O,O'-acac)(I^-acac)(DMS)] requires PKC-I' mediated p53 activation in malignant pleural mesothelioma. ( 29432478 )
2018
2
Expression analysis of High-mobility group box-1 (HMGB1) in histologic samples of malignant pleural mesothelioma. ( 29356044 )
2018
3
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma. ( 29362358 )
2018
4
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. ( 29444986 )
2018
5
Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma. ( 29946373 )
2018
6
PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma. ( 29908324 )
2018
7
Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study. ( 29967955 )
2018
8
Current surgical treatment of malignant pleural mesothelioma. ( 29980443 )
2018
9
Prostate-specific membrane antigen avidity on positron emission tomography scan in malignant pleural mesothelioma. ( 29873168 )
2018
10
Multiple intracranial metastases from postoperative giant sarcomatoid malignant pleural mesothelioma: A case report and literature review. ( 29387394 )
2018
11
Radical multimodality therapy for malignant pleural mesothelioma. ( 29309720 )
2018
12
An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. ( 29438360 )
2018
13
FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients. ( 29876617 )
2018
14
Biomarkers in malignant pleural mesothelioma: current status and future directions. ( 29850181 )
2018
15
Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival. ( 29413055 )
2018
16
A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol. ( 29853412 )
2018
17
Critical role of the Ror-family of receptor tyrosine kinases in invasion and proliferation of malignant pleural mesothelioma cells. ( 29845703 )
2018
18
Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma. ( 29931180 )
2018
19
Heterogeneity in Malignant Pleural Mesothelioma. ( 29848954 )
2018
20
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. ( 29346042 )
2018
21
Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. ( 29313814 )
2018
22
Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on. ( 29914087 )
2018
23
The management of malignant pleural mesothelioma in the USA 2004-13-a decade of lost opportunity? ( 29849196 )
2018
24
Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients. ( 29338319 )
2018
25
Variation in incidence trends of malignant pleural mesothelioma in Europe. ( 29437947 )
2018
26
Malignant Pleural Mesothelioma: The Last 8 Years of Experience in Our Area. ( 29804950 )
2018
27
Single-institution experience of intensity-modulated radiotherapy for malignant pleural mesothelioma at University of Catania. ( 29400553 )
2018
28
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. ( 29399399 )
2018
29
Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma. ( 29921948 )
2018
30
Is there a role for immunotherapy in malignant pleural mesothelioma? ( 29845408 )
2018
31
Revised Modified RECIST Criteria in Malignant Pleural Mesothelioma (Version 1.1): A Step Forward in a Long Race. ( 29935841 )
2018
32
Breast Metastasis from Malignant Pleural Mesothelioma: A Rare Challenging Entity. ( 29935848 )
2018
33
Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience. ( 29367501 )
2018
34
Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma. ( 29742520 )
2018
35
Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. ( 29804728 )
2018
36
Proton beam therapy for malignant pleural mesothelioma. ( 29876318 )
2018
37
Focal Adhesion Kinase a Potential Therapeutic Target for Pancreatic Cancer and Malignant Pleural Mesothelioma. ( 29303405 )
2018
38
<i>SFRP</i> Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma. ( 29386699 )
2017
39
Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma. ( 28027772 )
2017
40
Percutaneous Cryoablation for the Treatment of Recurrent Malignant Pleural Mesothelioma: Safety, Early-Term Efficacy, and Predictors of Local Recurrence. ( 27979596 )
2017
41
Radiotherapy for the treatment of malignant pleural mesothelioma. ( 28884702 )
2017
42
Open access phone triage for veterans with suspected malignant pleural mesothelioma. ( 27979465 )
2017
43
Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). ( 28862644 )
2017
44
Clinical staging of malignant pleural mesothelioma: current perspectives. ( 28860886 )
2017
45
Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma. ( 28197626 )
2017
46
BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma. ( 27771374 )
2017
47
Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma. ( 28948332 )
2017
48
Prognostic and predictive role of [(18) F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. ( 28941158 )
2017
49
The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review. ( 28859932 )
2017
50
Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma. ( 29371938 )
2017

Variations for Malignant Pleural Mesothelioma

Copy number variations for Malignant Pleural Mesothelioma from CNVD:

7 (show all 35)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13406 1 1 2300000 Loss Pleural malignant mesothelioma
2 21839 1 16200000 28000000 Loss Pleural malignant mesothelioma
3 33951 1 50700000 61300000 Amplification Pleural malignant mesothelioma
4 35953 1 69700000 116100000 Loss Pleural malignant mesothelioma
5 35955 1 69700000 116100000 Loss CLCA1 Pleural malignant mesothelioma
6 35957 1 69700000 116100000 Loss CLCA2 Pleural malignant mesothelioma
7 35959 1 69700000 116100000 Loss CLCA3 Pleural malignant mesothelioma
8 35961 1 69700000 116100000 Loss CLCA4 Pleural malignant mesothelioma
9 35963 1 69700000 116100000 Loss COL11A1 Pleural malignant mesothelioma
10 35965 1 69700000 116100000 Loss TGFBR3 Pleural malignant mesothelioma
11 35967 1 69700000 120600000 Loss Pleural malignant mesothelioma
12 37057 1 84900000 107200000 Loss Pleural malignant mesothelioma
13 69953 12 56600000 58100000 Gain Pleural malignant mesothelioma
14 75173 13 17900000 45800000 Loss BRCA2 Pleural malignant mesothelioma
15 85739 14 50900000 107349540 Loss CCNK Pleural malignant mesothelioma
16 85741 14 50900000 107349540 Loss CDKN3 Pleural malignant mesothelioma
17 113646 17 44900000 81195210 Gain ERN1 Pleural malignant mesothelioma
18 113648 17 44900000 81195210 Gain MAP3K3 Pleural malignant mesothelioma
19 113650 17 44900000 81195210 Gain PRKCA Pleural malignant mesothelioma
20 113652 17 44900000 81195210 Gain SMARCD2 Pleural malignant mesothelioma
21 175423 3 39400000 63700000 Loss CACNA2D3 Pleural malignant mesothelioma
22 175425 3 39400000 63700000 Loss CTNNB1 Pleural malignant mesothelioma
23 175427 3 39400000 63700000 Loss MLH1 Pleural malignant mesothelioma
24 175772 3 44100000 44200000 Loss Pleural malignant mesothelioma
25 187515 4 50400000 191154276 Loss Pleural malignant mesothelioma
26 191706 5 1 48400000 Gain Pleural malignant mesothelioma
27 204730 6 114600000 118300000 Loss HDAC2 Pleural malignant mesothelioma
28 204732 6 114600000 118300000 Loss MARCKS Pleural malignant mesothelioma
29 217076 7 1 4500000 Gain Pleural malignant mesothelioma
30 234872 8 139900000 146364022 Gain Pleural malignant mesothelioma
31 250027 9 19900000 25600000 Loss C9orf14 Pleural malignant mesothelioma
32 250030 9 19900000 25600000 Loss CDKN2A Pleural malignant mesothelioma
33 250032 9 19900000 25600000 Loss CDKN2B Pleural malignant mesothelioma
34 250070 9 19900000 33200000 Loss Pleural malignant mesothelioma
35 251885 9 33200000 36300000 Gain Pleural malignant mesothelioma

Expression for Malignant Pleural Mesothelioma

Search GEO for disease gene expression data for Malignant Pleural Mesothelioma.

Pathways for Malignant Pleural Mesothelioma

Pathways related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.47 CDH2 MET SPP1

GO Terms for Malignant Pleural Mesothelioma

Biological processes related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inhibition of cysteine-type endopeptidase activity involved in apoptotic process GO:1990001 8.96 BIRC5 XIAP
2 regulation of signal transduction GO:0009966 8.8 BIRC5 CDH2 XIAP

Sources for Malignant Pleural Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....